MarketCap
Facebook
X
TelegramQuarterly report 2022-Q3
added 05-16-2026
Aerie Pharmaceuticals Cash and Cash Equivalents 2011-2026 | AERI
Annual Cash and Cash Equivalents Aerie Pharmaceuticals
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 37.2 M | 152 M | 144 M | 203 M | 198 M | 198 M | 91.1 M | 85.6 M | 69.6 M | 2.92 M | 15.1 M | 3.27 M | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 203 M | 2.92 M | 99.9 M |
Quarterly Cash and Cash Equivalents Aerie Pharmaceuticals
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | 54.1 M | 39.4 M | 56.4 M | 37.2 M | 61.8 M | 80 M | 123 M | 152 M | 130 M | 151 M | 134 M | 144 M | 249 M | 109 M | 149 M | 203 M | 235 M | 271 M | 250 M | 198 M | 194 M | 243 M | 140 M | 198 M | 212 M | 58.5 M | 74.3 M | 91.1 M | 107 M | 101 M | 113 M | 85.6 M | 149 M | 27.9 M | 35.8 M | 69.6 M | 4.62 M | 69.6 M | 69.6 M | 2.92 M | 2.92 M | - | - | 15.1 M | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 271 M | 2.92 M | 116 M |
Cash and Cash Equivalents of other stocks in the Drug manufacturers industry
| Issuer | Cash and Cash Equivalents | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Evoke Pharma
EVOK
|
13.6 M | - | - | $ 36.6 M |  USA |
 |
Calliditas Therapeutics AB (publ)
CALT
|
974 M | - | -0.1 % | $ 2.03 B |  Schweden |
 |
AcelRx Pharmaceuticals
ACRX
|
5.89 M | - | 7.5 % | $ 6.35 M | USA |
 |
DURECT Corporation
DRRX
|
11 M | - | - | $ 50.1 M | USA |
 |
Adamis Pharmaceuticals Corporation
ADMP
|
1.08 M | - | 0.86 % | $ 117 M | USA |
 |
Agile Therapeutics
AGRX
|
2.56 M | - | 10.11 % | $ 58.2 M | USA |
 |
Alimera Sciences
ALIM
|
12.1 M | - | - | $ 142 M | USA |
 |
Cumberland Pharmaceuticals
CPIX
|
11.4 M | $ 5.52 | -0.18 % | $ 82 M | USA |
 |
Cronos Group
CRON
|
792 M | $ 2.71 | 1.57 % | $ 1.04 B |  Canada |
 |
Harrow Health
HROW
|
72.9 M | $ 32.02 | 3.76 % | $ 1.18 B | USA |
 |
Athenex
ATNX
|
30.4 M | - | -23.39 % | $ 1.76 M | USA |
 |
Avadel Pharmaceuticals plc
AVDL
|
51.4 M | - | - | $ 2.06 B |  France |
 |
Catalent
CTLT
|
289 M | - | - | $ 11.5 B | USA |
 |
HEXO Corp.
HEXO
|
83.2 M | - | 2.45 % | $ 38.1 M | Canada |
 |
Eagle Pharmaceuticals
EGRX
|
55.3 M | - | -39.89 % | $ 27.7 M | USA |
 |
Endo International plc
ENDP
|
778 M | - | - | $ 28.9 M |  Irlanda |
 |
Bausch Health Companies
BHC
|
947 M | $ 5.36 | -2.37 % | $ 1.96 B | Canada |
 |
Organogenesis Holdings
ORGO
|
93.7 M | $ 2.61 | 2.16 % | $ 331 M | USA |
 |
Pacira BioSciences
PCRX
|
277 M | $ 23.19 | 0.83 % | $ 1.07 B | USA |
 |
Canopy Growth Corporation
CGC
|
114 M | $ 1.06 | 2.91 % | $ 114 M | Canada |
 |
Solid Biosciences
SLDB
|
59.9 M | $ 6.45 | -0.31 % | $ 564 M | USA |
 |
Aurora Cannabis
ACB
|
138 M | $ 3.52 | 1.3 % | $ 193 M | Canada |
 |
Sonoma Pharmaceuticals
SNOA
|
5.37 M | $ 1.06 | -0.93 % | $ 1.32 M | USA |
 |
Jupiter Wellness
JUPW
|
2.28 M | - | - | $ 33.6 M | USA |
 |
Lannett Company
LCI
|
87.9 M | - | 1.15 % | $ 7.11 M | USA |
 |
OrganiGram Holdings
OGI
|
107 M | $ 1.12 | 4.67 % | $ 107 M | Canada |
 |
Tilray
TLRY
|
207 M | $ 5.37 | -0.74 % | $ 3.32 B | Canada |
 |
Evolus
EOLS
|
53.8 M | $ 6.49 | -1.52 % | $ 418 M | USA |
 |
Sundial Growers
SNDL
|
252 M | $ 1.46 | 1.04 % | $ 3.37 M | Canada |
 |
Emergent BioSolutions
EBS
|
112 M | $ 8.24 | 1.1 % | $ 422 M | USA |
 |
Veru
VERU
|
15.8 M | $ 2.16 | -0.46 % | $ 31.6 M | USA |
 |
Neoleukin Therapeutics
NLTX
|
104 M | - | - | $ 193 M | Canada |
 |
cbdMD
YCBD
|
2.26 M | $ 0.75 | 1.32 % | $ 3.02 M | USA |
 |
Assertio Holdings
ASRT
|
10.2 M | $ 23.43 | -0.06 % | $ 150 M | USA |
 |
ProPhase Labs
PRPH
|
9.11 M | - | - | $ 5.07 M | USA |
 |
Radius Health
RDUS
|
112 M | - | - | $ 1.42 B | USA |
 |
PetIQ
PETQ
|
116 M | - | 1.64 % | $ 400 M | USA |
 |
Relmada Therapeutics
RLMD
|
3.5 M | $ 7.15 | -0.28 % | $ 282 M | USA |
 |
Recro Pharma
REPH
|
8.1 M | - | -4.76 % | $ 65.3 M | USA |
 |
OptiNose
OPTN
|
73.7 M | - | - | $ 1.08 B | USA |
 |
SCYNEXIS
SCYX
|
21.3 M | $ 0.68 | 1.57 % | $ 34 M | USA |
 |
PLx Pharma
PLXP
|
69.4 M | - | -27.8 % | $ 2.56 M | USA |
 |
Viatris
VTRS
|
1.32 B | $ 16.32 | -1.66 % | $ 19 B | USA |
 |
Zomedica Corp.
ZOM
|
9.02 M | - | -0.21 % | $ 98 M | USA |
 |
Zynerba Pharmaceuticals
ZYNE
|
50.6 M | - | - | $ 55.5 M | USA |
 |
Rockwell Medical
RMTI
|
10.7 M | $ 0.8 | -2.78 % | $ 28.8 M | USA |
 |
Tricida
TCDA
|
21.1 M | - | - | $ 3.25 M | USA |
 |
China Pharma Holdings
CPHI
|
345 K | $ 0.7 | -6.77 % | $ 3 M |  China |
 |
TherapeuticsMD
TXMD
|
7.48 M | $ 2.07 | -0.72 % | $ 23.9 M | USA |